Recent Updates
Recently added Catalysts

bemiparin/day

Phase 2

Peritoneal Diseases | Small molecule | Other |Baxter International Inc.|Last Updated: May 14, 2010

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment76

FDA Designations

No designations recorded

Clinical trial landscape

bemiparin/day · 1 trial · 1 indication

Phase 2 1
NCT00369096Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina)Peritoneal Diseases
COMPLETED76 Analytics
PHASE2COMPLETED
Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina)
Peritoneal Diseases
NCT0036909676
Unlock trial analytics

Study Endpoints

Primary Endpoints

Efficacy: Peritoneal function defined according to the standardized ultrafiltration capacity and/or estimated peritoneal creatinine transport estimated by D/P and mass transfer coefficient during randomized treatment

Secondary Endpoints

Safety: Incidence of peritonitis during the randomized treatment period, defined by a cell count of peritoneal effluent with more than 100 leukocytes per mm3 with 50% or more polymorphonuclear cells
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
bemiparin 3500 IU/dayDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites17

Inclusion Criteria: 1. Patients over 18 years old, of either sex, who have given their informed consent to participate in the study. 2. Patients in stable treatment with peritoneal dialysis for more than 6 weeks who present peritoneal dysfunction defined by capacity for standardized ultrafiltration...

Countries:Spain
Unlock Eligibility Criteria

Frequently asked questions about bemiparin/day

What is bemiparin/day used for?

Bemiparin/day is an investigational small molecule being studied for peritoneal diseases, specifically as an addition to icodextrin solution in peritoneal dialysis patients. It is currently in Phase 2 clinical development and is not approved for any use.

Who makes bemiparin/day?

Bemiparin/day is being developed by Baxter International Inc., a company traded on the New York Stock Exchange under the ticker symbol BAX. The drug is currently in Phase 2 clinical trials for peritoneal diseases.

What phase is bemiparin/day in?

Bemiparin/day is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is not currently in active trials.

What clinical trials is bemiparin/day in?

Bemiparin/day has been studied in one completed Phase 2 clinical trial, identified as NCT00369096. This trial, titled 'Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina)', enrolled 76 participants in Spain.

Is bemiparin/day the same as Bemidextrina?

Bemiparin/day is associated with the trial name Bemidextrina, which refers to the study of bemiparin added to icodextrin solution. The drug itself is bemiparin, and the trial is known as the Bemidextrina study.